On 12 Nov 2026 Insulet Corporation closed at $149.29, -47.5% this year; market cap $10.37bn, P/E 24.2.
Health Care · Health Care Equipment · NASDAQ · United States
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Market cap | $10.37bn |
| P/E (trailing) | 24.2 |
| EPS (TTM) | $6.17 |
| Beta | 1.05 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 4 Nov 2026 |
| Next earnings | 3 Feb 2027 |
| YTD | -47.5% |
| 1Y | -55.7% |
| 3Y | -3.0% |
| 5Y | -13.9% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $2.71bn | $247.10m | $377.70m |
| 2024 | $2.07bn | $418.30m | $305.40m |
| 2023 | $1.70bn | $206.30m | $70.10m |
| 2022 | $1.31bn | $4.60m | $-38.30m |
| 2021 | $1.10bn | $16.80m | $-190.80m |
Base value $155.36 (+4.1% vs price); 1 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.